Early Detection of Pancreatic Cancer

胰腺癌的早期发现

• 批准号: 7267972
• 负责人: RANDY S. HAUN
• 金额: $ 11.79万
• 依托单位: UNIV OF ARKANSAS FOR MED SCIS
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7267972
• 关键词: Amino Acid Sequence; Anorexia; Arts; Back Pain; Basic Science; Benign; Biological Markers; Body Weight decreased; Cancer Control; Cancer Detection; Cancer Patient; Classification; Clinic; Clinical; Clinical Skills; Detection; Diagnosis; Diagnostic; Disease; Early Diagnosis; Endoscopic Ultrasonography; Epigastric; Excision; Exhibits; Fingerprint; Goals; Health Personnel; Image; Incidence; Individual; Intervention; Lesion; Liquid Chromatography; Liquid substance; Magnetic Resonance; Malignant Neoplasms; Malignant neoplasm of pancreas; Mass Spectrum Analysis; Methods; Modeling; Monitor; Numbers; Operative Surgical Procedures; Pancreas; Pancreatic Adenocarcinoma; Pancreatic Diseases; Pancreatic carcinoma; Patients; Peptide Sequence Determination; Peptides; Population; Procedures; Proteins; Proteomics; Purpose; Range; Rate; Resectable; Risk; Sampling; Scientist; Screening procedure; Sensitivity and Specificity; Serum; Serum Proteins; Spectrometry; Staging; Surgical Oncologist; Symptoms; System; Techniques; Technology; Testing; Time; Today; Translations; United States; X-Ray Computed Tomography; base; experience; gastrointestinal; interest; neoplastic; novel; pancreas imaging; size; surface enhanced laser desorption ionization; tandem mass spectrometry; tool; tumor; two-dimensional

DESCRIPTION (provided by applicant): Project Summary: Pancreatic cancer (PaC) is a devastating and poorly understood cancer. In the year 2005, an estimated 32,180 new cases of pancreatic adenocarcinoma are projected to be diagnosed, of which 31,800 are expected to die from this disease. Symptoms of pancreatic carcinoma including weight loss, anorexia, epigastric discomfort, and back pain are non-specific and vague, so diagnosis may be considerably delayed. Consequently fewer than 20% of patients have resectable disease by the time the diagnosis is made. Thus, among the most compelling needs for PaC today is to develop a rational, evidence-based strategy to screen for early PaC. The purpose of the proposed studies is to identify novel biomarkers that will aid in the diagnosis of early pancreatic cancer. Towards this goal we have assembled a strong investigative team that includes basic scientists with extensive experience in proteomics and biostatistical expertise combined with the clinical skills of surgical oncologists with a particular interest in early detection and treatment of pancreatic cancer. A state-of-the-art two-dimensional liquid chromatography system will be used to prepare serum protein profiles from patients with resectable PaC and control subjects that include patients with benign pancreatic disease, other gastrointestinal malignancies, and healthy individuals. Classification models comprised of a panel of biomarkers that can correctly classify PaC patient serum from controls will be derived from the protein profiles and verified using an independent set of serum protein profiles. The individual proteins composing the panel of biomarkers will then be identified by tandem mass spectrometry. Changes in the serum level of these potential diagnostic biomarkers will also be monitored in serum collected postoperatively from patients who have undergone pancreatic resection for PaC. Using cutting-edge proteomic technologies, we anticipate the identification of a panel of biomarkers that may be used for early detection of this devastating disease; thus allowing us to rapidly advance the translation of our basic science findings into the clinic. Relevance: Currently, there are no reliable screening tests available for early diagnosis of pancreatic cancer. As surgical resection is the only curative intervention for pancreatic cancer, there is a desperate need for better methods of detection of this disease at an early, operable stage. In this study, we will use state-of-the- art technologies to identify proteins in serum that may be used for early detection of pancreatic cancer and thus have a profound impact upon the diagnosis and treatment of patients with this disease.

描述（由申请人提供）： 项目摘要：胰腺癌 (PaC) 是一种破坏性且人们知之甚少的癌症。 2005年，预计将诊断出32,180例新的胰腺癌病例，其中预计将有31,800人死于这种疾病。胰腺癌的症状包括体重减轻、厌食、上腹不适和背痛，这些症状是非特异性且模糊的，因此诊断可能会大大延迟。因此，在做出诊断时，只有不到 20% 的患者患有可切除的疾病。因此，当今 PaC 最迫切的需求之一是制定合理的、基于证据的策略来筛查早期 PaC。拟议研究的目的是确定有助于诊断早期胰腺癌的新型生物标志物。为了实现这一目标，我们组建了一支强大的研究团队，其中包括在蛋白质组学和生物统计学专业知识方面拥有丰富经验的基础科学家，以及对胰腺癌的早期检测和治疗特别感兴趣的外科肿瘤学家的临床技能。最先进的二维液相色谱系统将用于制备可切除 PaC 患者和对照受试者（包括良性胰腺疾病、其他胃肠道恶性肿瘤患者和健康个体）的血清蛋白谱。由一组生物标志物组成的分类模型可以从蛋白质谱中正确分类 PaC 患者血清和对照，并使用一组独立的血清蛋白质谱进行验证。然后通过串联质谱法鉴定组成生物标志物组的各个蛋白质。还将在接受 PaC 胰腺切除术的患者术后收集的血清中监测这些潜在诊断生物标志物血清水平的变化。利用尖端的蛋白质组学技术，我们预计将鉴定出一组可用于早期检测这种毁灭性疾病的生物标志物；从而使我们能够快速推进将基础科学发现转化为临床。相关性：目前，没有可靠的筛查测试可用于胰腺癌的早期诊断。由于手术切除是胰腺癌的唯一治疗方法，因此迫切需要更好的方法在早期、可手术阶段检测这种疾病。在这项研究中，我们将使用最先进的技术来鉴定血清中的蛋白质，这些蛋白质可用于早期检测胰腺癌，从而对该疾病患者的诊断和治疗产生深远的影响。

项目成果

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.

• DOI: 10.1186/1471-2407-13-404
• 发表时间: 2013-09-03
• 期刊: BMC cancer
• 影响因子: 3.8
• 作者: Makawita S;Dimitromanolakis A;Soosaipillai A;Soleas I;Chan A;Gallinger S;Haun RS;Blasutig IM;Diamandis EP
• 通讯作者: Diamandis EP